SK Biopharmaceuticals Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SK Biopharmaceuticals Co., Ltd
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
The Korean microbiome therapeutics developer KoBioLabs will launch a domestic IPO later this month and hopes to grow into a top three global company in the sector by 2025, helped by licensing deals.
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.
- Drug Delivery
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- SK Holdings
- SK Life Science, Inc.
- SK Biofarm Co., Ltd.